Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention

European Heart Journal

Volumn 30, Issue 21, 2009, Pages 2614-2621

  De La Hera, Jesús M ^a   Delgado, Elías ^a   Hernández, Ernesto ^a   García Ruiz, José M ^a   Vegas, José M ^a   Avanzas, Pablo ^a   Lozano, Iñigo ^a   Barriales Villa, Roberto ^a   Hevia, Sergio ^a   Martín, Julia San ^a   Alvarez, Francisco ^a   Morís, César ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Coronary angioplasty; Diabetes mellitus; Impaired glucose regulation; Oral glucose tolerance test

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS;

AGED; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70449481538     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp278     Document Type: Article

References (31)

1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: US Department of Health and Human Services, National Institute of Health 2005.
2. The DECODE Study Group. Age-and sex-specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26: 61-69.
3. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, DAgostino RB. Trends in the incidence of type 2 diabetes mellitus from 1970s to the 1990s: the Framingham Heart Study. Circulation 2006;113:2914-2918.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053.
5. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144.
6. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-1890.
7. Hu DY, Pan CY, Yu JM, for the China Heart Survey Group. The relationship between coronary artery disease an abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006;27:2573-2579.
8. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, Pearson RR, Carlquist JF. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003;146:351-358.
9. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation 2004;109:476-480.
10. Wilson SR, Vakili BA, Sherman W, Sanborn TA, Brown DL. Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases. Diabetes Care 2004;27:1137-1142.
11. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
12. Thygesen K, Alpert JS, White HD, on behalf on the joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653.
13. Alberti KG, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28: 412-419.
15. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation coronary syndromes. Eur Heart J 2004;25:190-198.
16. Anderson HV, Shaw RE, Brindis RG, McKay CR, Klein LW, Krone RJ, Ho KK, Rumsfeld JS, Smith SC Jr, Weintraub WS. Risk-Adjusted Mortality Analysis of Percutaneous Coronary Interventions by American College of Cardiology/American Heart Association Guidelines Recommendations. Am J Cardiol 2007;99:189-196.
17. Lincoff M. Important Triad in Cardiovascular Medicine: Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Receptor Blockade. Circulation 2003; 107:1556-1559.
18. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet glyco-protein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767-2771.
19. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC, for the RAVEL Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J 2004;25:107-112.
20. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-2285.
21. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol 2007; 100:770-776.
22. Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L, on behalf of the Euro ]Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008;29:177-184.
23. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393. (Pubitemid 36159355)
24. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte OP, Reimer W, Simoons WL, on behalf of the Euro Heart Survey Investigators. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006;27: 2969-2974.
25. Otten R, Kline-Rogers E, Meier DJ, Dumasia R, Fang J, May N, Resin Y, Armstrong DF, Saab F, Petrina M, Eagle KA, Mukherjee D. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart 2005; 91:1466-1468.
26. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 2007;116:151-157.
27. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, Hulley S, Barrett-Connor E. Impaired fasting glucose and cardiovascular outcomes in post-menopausal women with coronary artery disease. Ann Intern Med 2005;142: 813-820.
28. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999;22:45-49.
29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
30. The DREAM Trial Investigators, Gerstein HC, Yusuf S, Bosc J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105.
31. Wallander M, Malmberg K, Norhammar A, Rydén L, Tenerz A. Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 2008;31:36-38